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By the year 2050 one-fifth of the world population will sur-
pass 80 years of age.1
The prevalence of arterial hypertension (AH) increases
with aging. In fact, the vast majority of the elderly are af-
fected with AH. The Framingham study demonstrated that
almost two-thirds of males and three quarter of females
develop AH by the age of 70 years.2,3
Managing blood pressure is often difficult in the elderly,
not only because of comorbidities, but also due to vascular
remodelling and the changes in the renal and endocrine
physiology. The structural and functional arterial modifica-
tions lead to impaired vessel’s compliance and increased
systolic blood pressure (SBP), often with reduction of
diastolic blood pressure (DBP). Hence isolated systolic
hypertension, characterized by SBP >140mmHg and
DBP <90mmHg, is more common in the elderly.4,5 In the
old patient with AH common comorbidity are coronary
artery disease (CAD), heart failure, renal dysfunction,
cerebrovascular disease, peripheral arterial disease, and
cognitive disorders, all interfering with the natural history
of AH and complicating both the therapeutic management
and the prognosis.2
Data concerning patients over the age of 80years and
‘frail’ patients are more controversial. The latter, albeit
at higher risk for cardiovascular diseases (CVD), seem to
benefit less from antihypertensive treatment while often
incurring in the side effects of treatment. Recent studies
suggest a tempering of the correlation between high blood
pressure and mortality in ‘frail’ patients, identified by slow
walking (surrogatemarker of frailty).6
The latest guidelines of the European Society of
Hypertension (ESH)/European Society of Cardiology (ESC),
incorporating the evidences suggesting antihypertensive
treatment in the elderly only for SBP 160 mmHg, recom-
mended a blood pressure target for SBP <150mmHg,
reaching cautiously a level of <140mmHg whenever possi-
ble. Nonetheless, for patients under the age of 80 years,
antihypertensive treatment can be considered for SBP
>140mmHg, with the goal to reach values <140mmHg in
suitable patients tolerating the treatment well. On the
other hand, elderly ‘frail’ patients should be treated
with caution, carefully considering their comorbidities.
Protracting the treatment over the 80years of age, when
well tolerated, could be considered.7
The ideal target for DBP in the elderly is a still unan-
swered question. In the SHEP study, cardiovascular risk in-
creased in treated patients for DBP <70mmHg. The Syst-
Eur Trial revealed that in patients with CAD, a reduction of
DBP <70mmHg carried a higher risk of CVD.8,9 The ‘J’
curve phenomenon has been the object of debate since its
introduction by Cruickshank in 1979. Several evidences sug-
gest an increased risk of myocardial infarction, but not of
renal diseases, particularly in patients with pre-existing
CAD, when the DBP is <85/90mmHg. Some epidemiologic
study would suggest DBP levels higher for certain groups
of elderly. It is plausible that ‘frail’ elderly (patients with
previous cerebrovascular events) would benefit from
higher blood pressure to keep a satisfactory perfusion of
the target organs.10 A sensible clinical practice could be
treating hypertension in the elderly by cautiously reaching
a target SBP of 140mmHg, whereas carefully avoiding a
DBP<70mmHg, as tomaintain tissue perfusion.
Figure 1 shows the prevalence of AH treated according
to various SBP targets in the outpatient population at
the Sant’Andrea Hospital-University of Rome ‘la Sapienza’.
More than 60% of the patients over 65years of age reached
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a SBP<150mmHg. The number increases to almost 70% for
patients over the age of 80 years. About 40% of hyperten-
sive patients over the age of 65years, once treated, reach
a SBP<140mmHg, andmore than 20% SBP<130mmHg.
Considering all available data, the recommendation for a
blood pressure target in the elderly should be cautious, tak-
ing into account more the individual characteristics than a
general guidelines. Epidemiology data reporting significant
benefit in treating elderly ‘healthy’ patients are solid, but
we are all well aware that treating ‘frail’ elderly patient,
with all their comorbidities and susceptibility to the side ef-
fect of drug treatment, could be challenging. The ‘biologic’
age appears to be more important than the ‘anagraphic’
age, and it should take precedence in considering antihy-
pertensive treatment, which should be effectively ‘person-
alized’ in the elderly. Whether some patients over the age
of 65years could tolerate well intensive antihypertensive
treatment, with therapeutic targets similar to the younger
patients, for other patients a less ambitious target, such as
<150/90mmHg, could be reasonable, particularly in the
‘over 80’, until more specific data will become available.
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